Natco Pharma (NSE:NATCOPHARM) Asset Turnover: 0.07 (As of Mar. 2026)


NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
89 GF Score
Price ₹984.10
GF Value ₹932.30
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Asset Turnover?

Natco Pharma NSE:NATCOPHARM +2.34% 89 Asset Turnover is 0.07 as of Mar. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹932.30 (Fairly Valued). The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Natco Pharma's Revenue for the three months ended in Mar. 2026 was ₹7,391 Mil. Natco Pharma's Total Assets for the quarter that ended in Mar. 2026 was ₹110,737 Mil. Therefore, Natco Pharma's Asset Turnover for the quarter that ended in Mar. 2026 was 0.07.

Asset Turnover is linked to ROE % through Du Pont Formula. Natco Pharma's annualized ROE % for the quarter that ended in Mar. 2026 was 11.62%. It is also linked to ROA % through Du Pont Formula. Natco Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was 9.68%.


Natco Pharma  (NSE:NATCOPHARM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Natco Pharma's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=10716/92211
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(10716 / 29564)*(29564 / 110737)*(110737/ 92211)
=Net Margin %*Asset Turnover*Equity Multiplier
=36.25 %*0.267*1.2009
=ROA %*Equity Multiplier
=9.68 %*1.2009
=11.62 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Natco Pharma's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=10716/110737
=(Net Income / Revenue)*(Revenue / Total Assets)
=(10716 / 29564)*(29564 / 110737)
=Net Margin %*Asset Turnover
=36.25 %*0.267
=9.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Natco Pharma Asset Turnover Related Terms


Natco Pharma Asset Turnover Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Asset Turnover Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.50 0.63 0.57 0.41

Natco Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.15 0.13 0.06 0.07

NSE:NATCOPHARM vs ZTS, UTHR: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Asset Turnover falls into.


NSE:NATCOPHARM
89GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Natco Pharma's Asset Turnover for the fiscal year that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2026 )/( (Total Assets (A: Mar. 2025 )+Total Assets (A: Mar. 2026 ))/ count )
=40783/( (86308+110737)/ 2 )
=40783/98522.5
=0.41

Natco Pharma's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=7391/( (0+110737)/ 1 )
=7391/110737
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.07 mean?
Natco Pharma (NSE:NATCOPHARM) has a Asset Turnover of 0.07 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's Asset Turnover too high?
Natco Pharma's current Asset Turnover is 0.07. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Asset Turnover compare to ZTS and UTHR?
Natco Pharma's Asset Turnover of 0.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Natco Pharma and its competitors. Natco Pharma's current Asset Turnover is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹932.30, compared to a current price of ₹984.10 — trading 5.6% above its estimated fair value. The current Asset Turnover is 0.07. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Asset Turnover is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued. The current stock price of ₹984.10 is trading 5.6% above its estimated GF Value™ of ₹932.30. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • Asset Turnover: 0.07
  • GF Value™: ₹932.30 vs. price of ₹984.10 (5.6% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score

Get the complete analysis for NSE:NATCOPHARM

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹984.10
Price
₹932.30
GF Value